Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SOAT1 | P35610 | 8/20 | 1.00 |
| ▸ | LMNA | P02545 | 3/20 | 0.49 |
| ▸ | GAA | P10253 | 1/20 | 0.49 |
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | MPO | P05164 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | GRIN2A | Q12879 | 1/20 | 0.45 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29845569 | 1.00 | SOAT1 (1.00) | SOAT1LMNAGAARAB9AMAPT | |
| Hydrochloric Acid SCHEMBL1704627 | 0.99 | SOAT1 (1.00) | SOAT1LMNAGAARAB9AMAPT | |
| Hydrochloric Acid SCHEMBL29972967 | 0.99 | SOAT1 (1.00) | SOAT1LMNAGAARAB9AMAPT | |
| Hydrochloric Acid SCHEMBL6283825 | 0.99 | SOAT1 (1.00) | SOAT1LMNAGAARAB9AMAPT | |
| SCHEMBL16696509 | 0.92 | SOAT1 (0.85) | SOAT1LMNAGAARAB9AMAPT | |
| SCHEMBL6279700 | 0.92 | SOAT1 (0.84) | SOAT1LMNAGAARAB9AMAPT | |
| SCHEMBL6279708 | 0.91 | SOAT1 (0.83) | SOAT1LMNAGAARAB9AMAPT | |
| SCHEMBL6279621 | 0.90 | SOAT1 (0.81) | SOAT1LMNAGAARAB9AMAPT | |
| SCHEMBL6278420 | 0.89 | SOAT1 (0.80) | SOAT1LMNAGAARAB9AMAPT | |
| SCHEMBL6760737 | 0.89 | SOAT1 (0.79) | SOAT1RAB9AMAPTMAPK1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 132 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190247397-A1 | COMBINATORY TREATMENT STRATEGIES OF CANCER BASED ON RNA POLYMERASE I INHIBITION | THE JOHNS HOPKINS UNIVERSITY | 2019-08-15 | — | — | US | claimed |
| EP-2573081-B1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR NON-ALCOHOLIC STEATOHEPATITIS | KOWA CO (JP) | 2017-07-12 | — | — | EP | claimed |
| US-20140221390-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR NON-ALCOHOLIC STEATOHEPATITIS | KOWA COMPANY, LTD. (JP) | 2014-08-07 | — | — | US | claimed |
| EP-2573081-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR NON-ALCOHOLIC STEATOHEPATITIS | Kowa Company Ltd. (JP) | 2013-03-27 | — | — | EP | claimed |
| US-20130066075-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR NON-ALCOHOLIC STEATOHEPATITIS | KOWA COMPANY, LTD. (JP) | 2013-03-14 | — | — | US | claimed |
| US-20130035344-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | KOWA CO., LTD. (JP) | 2013-02-07 | — | — | US | claimed |
| US-20120289517-A1 | SOLID PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | KOWA CO., LTD. (JP) | 2012-11-15 | — | — | US | claimed |
| EP-2520300-A1 | PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | Kowa Co., Ltd. (JP) | 2012-11-07 | — | — | EP | claimed |
| EP-2520299-A1 | SOLID PHARMACEUTICAL COMPOSITION FOR ORAL ADMINISTRATION | Kowa Co., Ltd. (JP) | 2012-11-07 | — | — | EP | claimed |
| EP-1598346-B1 | PROCESS FOR PRODUCING ACID ADDUCT SALT OF POLYACIDIC BASE COMPOUND | KOWA CO (JP) | 2012-04-18 | — | — | EP | claimed |
| US-7884106-B2 | administering 2-[4-[2-(benzimidazol-2-ylthio)ethyl]piperazin-1-yl]-N-[2,4-bis(methylthio)-6-methyl-3-pyridyl]acetamide; treating thrombogenesis, acute coronary syndrome, acute myocardial infarction, unstable angina, peripheral artery obstruction | KOWA COMPANY, LTD. (JP) | 2011-02-08 | — | — | US | claimed |
| US-20110015206-A1 | METHOD OF STABILIZING LIPID-RICH PLAQUE AND METHOD OF PREVENTING RUPTURE THEREOF | KOWA CO., LTD. (JP) | 2011-01-20 | — | — | US | claimed |
| US-7750150-B2 | Process for producing acid adduct salt of polyacidic base compound | KOWA CO., LTD. (JP) | 2010-07-06 | — | — | US | claimed |
| US-20090275595-A1 | METHOD FOR REDUCTION, STABILIZATION AND PREVENTION OF RUPTURE OF LIPID RICH PLAQUE | KOWA CO., LTD. (JP) | 2009-11-05 | — | — | US | claimed |
| EP-1827440-A1 | METHOD FOR REDUCTION, STABILIZATION AND PREVENTION OF RUPTURE OF LIPID RICH PLAQUE | Kowa Co., Ltd. (JP) | 2007-09-05 | — | — | EP | claimed |
| US-20070004749-A1 | Method of stabilizing lipid-rich plaque and method of preventing rupture thereof | KOWA CO., LTD. (JP) | 2007-01-04 | — | — | US | claimed |
| WO-2006064889-A1 | METHOD FOR REDUCTION, STABILIZATION AND PREVENTION OF RUPTURE OF LIPID RICH PLAQUE | KOWA CO., LTD. (JP) | 2006-06-22 | — | — | WO | claimed |
| EP-1666038-A1 | METHOD OF STABILIZING LIPID-RICH PLAQUE AND METHOD OF PREVENTING RUPTURE THEREOF | Kowa Co., Ltd. (JP) | 2006-06-07 | — | — | EP | claimed |
| US-20060079688-A1 | Process for producing acid adduct salt of polyacidic base compound | KOWA CO., LTD. (JP) | 2006-04-13 | — | — | US | claimed |
| EP-1598346-A1 | PROCESS FOR PRODUCING ACID ADDUCT SALT OF POLYACIDIC BASE COMPOUND | Kowa Co., Ltd. (JP) | 2005-11-23 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140221390-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR NON-ALCOHOLIC STEATOHEPATITIS | FABP1, LIPC, ACAT2 | SOAT1 62/4885LMNA 1137/4885GAA 449/4885 |
| US-20060079688-A1 | Process for producing acid adduct salt of polyacidic base compound | CA5B, ASIC1, NAAA | SOAT1 2641/4885LMNA 1421/4885GAA 542/4885 |
| US-20190247397-A1 | COMBINATORY TREATMENT STRATEGIES OF CANCER BASED ON RNA POLYMERASE I INHIBITION | ACAT1, PARP1, POLRMT | SOAT1 238/4885LMNA 2273/4885GAA 230/4885 |
| US-20130066075-A1 | PROPHYLACTIC AND/OR THERAPEUTIC AGENT FOR NON-ALCOHOLIC STEATOHEPATITIS | FABP1, LIPC, ACAT2 | SOAT1 62/4885LMNA 1137/4885GAA 449/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.